Literature DB >> 10215759

Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children.

J Anhøj1, H Bisgaard, B J Lipworth.   

Abstract

AIMS: The effect of the electrostatic charge in plastic spacers in vivo on drug delivery to the lung of hydrofluoroalkane (HFA) salbutamol spray was studied in children.
METHODS: Five children, aged 7-12 years, were included in a 3-way crossover randomised single-blind trial. Salbutamol HFA spray was delivered on 3 different study days from plastic spacers with mouthpiece. Pre-treatment of the spacers differed between study days: (a) Non-electrostatic 350 ml Babyhaler (coated with benzalkonium chloride) (b) New 350 ml Babyhaler (rinsed in water), and (c) New 145 ml AeroChamber (rinsed in water). Plasma salbutamol was measured before and 5, 10, 15 and 20 min after inhalation of four single puffs of 100 microg salbutamol. Cmax and Cav (5-20min) were calculated as a reflection of lung dose.
RESULTS: For Cmax: (A) Non-electrostatic Babyhaler 4.3 ng ml(-1) (B) New Babyhaler 1.9 ng ml(-1) (C) New AeroChamber 1.6 ng ml(-1): AvsB (95% CI for difference 0.5-4.5 ng ml(-1)), A vs C (95% CI for difference 0.7-4.8 ng ml(-1)). The geometric mean ratio for A:B was 2.4 fold, and for A:C was 2.9 fold. The values for Cav were similar with ratios for A:B of 2.4 fold, and A: C of 4.1 fold. The nonelectrostatic Babyhaler delivered a significantly (P<0.05) higher lung dose (for both Cmax and Cav) than either of the other two spacers.
CONCLUSIONS: The electrostatic charge in plastic spacers reduces lung dose in children by more than two-fold. This is clinically significant and the use of potentially electrostatically charged spacers should be avoided.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215759      PMCID: PMC2014226          DOI: 10.1046/j.1365-2125.1999.00893.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children.

Authors:  E Berg; J Madsen; H Bisgaard
Journal:  Eur Respir J       Date:  1998-08       Impact factor: 16.671

2.  Lung bioavailability of generic and innovator salbutamol MDIs.

Authors:  H Chrystyn; S A Corlett; V Silkstone
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

3.  Electrostatic charge on a plastic spacer device influences the delivery of salbutamol.

Authors:  J H Wildhaber; S G Devadason; M J Hayden; R James; A P Dufty; R A Fox; Q A Summers; P N LeSouëf
Journal:  Eur Respir J       Date:  1996-09       Impact factor: 16.671

4.  Drug delivery from inhaler devices.

Authors:  H Bisgaard
Journal:  BMJ       Date:  1996-10-12

5.  Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol.

Authors:  D J Clark; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1996-03       Impact factor: 4.335

Review 6.  Pharmacokinetics of inhaled drugs.

Authors:  B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1996-12       Impact factor: 4.335

7.  Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device.

Authors:  D J Clark; B J Lipworth
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

8.  A non-electrostatic spacer for aerosol delivery.

Authors:  H Bisgaard; J Anhøj; B Klug; E Berg
Journal:  Arch Dis Child       Date:  1995-09       Impact factor: 3.791

9.  The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler.

Authors:  P W Barry; C O'Callaghan
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

Review 10.  New perspectives on inhaled drug delivery and systemic bioactivity.

Authors:  B J Lipworth
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

View more
  12 in total

1.  Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children.

Authors:  Brian J Lipworth; Daniel K C Lee; Jacob Anhøj; Hans Bisgaard
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 2.  A path to successful patient outcomes through aerosol drug delivery to children: a narrative review.

Authors:  Arzu Ari
Journal:  Ann Transl Med       Date:  2021-04

3.  Comparative lung bioavailability of fluticasone/salmeterol via a breath-actuated spacer and conventional plastic spacers.

Authors:  Arun Nair; Lorna McKinlay; Peter Williamson; Philip Short; Patricia Burns; Brian J Lipworth
Journal:  Eur J Clin Pharmacol       Date:  2011-01-15       Impact factor: 2.953

4.  Response to albuterol MDI delivered through an anti-static chamber during nocturnal bronchospasm.

Authors:  Sreekala Prabhakaran; Jonathan Shuster; Sarah Chesrown; Leslie Hendeles
Journal:  Respir Care       Date:  2012-02-17       Impact factor: 2.258

5.  Respirable dose delivery of fluticasone propionate from a small valved holding chamber, a compact breath actuated integrated vortex device and a metered dose inhaler.

Authors:  Arun Nair; Daniel Menzies; Martyn Barnes; Patricia Burns; Lesley McFarlane; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

6.  The influence of actuator materials and nozzle designs on electrostatic charge of pressurised metered dose inhaler (pMDI) formulations.

Authors:  Yang Chen; Paul M Young; David F Fletcher; Hak Kim Chan; Edward Long; David Lewis; Tanya Church; Daniela Traini
Journal:  Pharm Res       Date:  2013-12-03       Impact factor: 4.200

Review 7.  Drug delivery interfaces: A way to optimize inhalation therapy in spontaneously breathing children.

Authors:  Arzu Ari
Journal:  World J Clin Pediatr       Date:  2016-08-08

8.  In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler.

Authors:  Arun Nair; Daniel Menzies; Pippa Hopkinson; Lesley McFarlane; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2009-02-09       Impact factor: 4.335

Review 9.  Use of inhaler devices in pediatric asthma.

Authors:  Fernando Maria De Benedictis; David Selvaggio
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 10.  Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting.

Authors:  Barbara P Yawn; Gene L Colice; Rick Hodder
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.